Novel remyelination strategy for multiple sclerosis in the era of oligodendrocytopathy

Research output: Contribution to journalArticle

Abstract

Spontaneous remyelination occurs in many early multiple sclerosis (MS) patients, however its capacity decreases as the disease becomes chronic. Even in those chronic MS patients, an enough number of oligodendrocyte precursor cells (OPCs) are preserved within the demyelinated lesions, suggesting that the differentiation arrest of oligodendroglial cells underlies the remyelination failure in chronic MS. We have previously reported that TIP30, a factor inhibiting nucleocytoplasmic transport within the cell, is responsible for the differentiation arrest in MS lesions. Overexpression of TIP30 in the preserved OPCs in MS lesions results in the failure of nuclear translocation of transcription factors necessary for oligodendroglial differentiation. Therefore, anti-TIP30 therapy to regain the nuclear access within the OPCs is necessary for sufficient remyelination in chronic MS patients. Moreover, inflammatory conditions surrounding OPCs may be involved in the efficient remyelination in early MS lesions, alternative stimulatory factor may therefore be mandatory to induce OPC differentiation into oligodendrocytes within the chronic lesion. We have previously reported that targeting FcRy protein on OPCs may stimulate their differentiation and consequently remyelination in the chronic lesions. A timely collaboration of these two approaches may be required for successful remyelination and neurological recovery in chronic MS patients.

Original languageEnglish
Pages (from-to)1351-1353
Number of pages3
JournalClinical Neurology
Volume52
Issue number11
DOIs
Publication statusPublished - 2012

Fingerprint

Oligodendroglia
Multiple Sclerosis
Cell Nucleus Active Transport
Protein Transport
Cell Differentiation
Chronic Disease
Transcription Factors

Keywords

  • FcRγ
  • Multiple sclerosis
  • Oligodendrocytopathy
  • Remyelination
  • TIP30

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Novel remyelination strategy for multiple sclerosis in the era of oligodendrocytopathy. / Nakahara, Jin.

In: Clinical Neurology, Vol. 52, No. 11, 2012, p. 1351-1353.

Research output: Contribution to journalArticle

@article{62e1e49e6ed74c0ea921a1fd75d61acc,
title = "Novel remyelination strategy for multiple sclerosis in the era of oligodendrocytopathy",
abstract = "Spontaneous remyelination occurs in many early multiple sclerosis (MS) patients, however its capacity decreases as the disease becomes chronic. Even in those chronic MS patients, an enough number of oligodendrocyte precursor cells (OPCs) are preserved within the demyelinated lesions, suggesting that the differentiation arrest of oligodendroglial cells underlies the remyelination failure in chronic MS. We have previously reported that TIP30, a factor inhibiting nucleocytoplasmic transport within the cell, is responsible for the differentiation arrest in MS lesions. Overexpression of TIP30 in the preserved OPCs in MS lesions results in the failure of nuclear translocation of transcription factors necessary for oligodendroglial differentiation. Therefore, anti-TIP30 therapy to regain the nuclear access within the OPCs is necessary for sufficient remyelination in chronic MS patients. Moreover, inflammatory conditions surrounding OPCs may be involved in the efficient remyelination in early MS lesions, alternative stimulatory factor may therefore be mandatory to induce OPC differentiation into oligodendrocytes within the chronic lesion. We have previously reported that targeting FcRy protein on OPCs may stimulate their differentiation and consequently remyelination in the chronic lesions. A timely collaboration of these two approaches may be required for successful remyelination and neurological recovery in chronic MS patients.",
keywords = "FcRγ, Multiple sclerosis, Oligodendrocytopathy, Remyelination, TIP30",
author = "Jin Nakahara",
year = "2012",
doi = "10.5692/clinicalneurol.52.1351",
language = "English",
volume = "52",
pages = "1351--1353",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Novel remyelination strategy for multiple sclerosis in the era of oligodendrocytopathy

AU - Nakahara, Jin

PY - 2012

Y1 - 2012

N2 - Spontaneous remyelination occurs in many early multiple sclerosis (MS) patients, however its capacity decreases as the disease becomes chronic. Even in those chronic MS patients, an enough number of oligodendrocyte precursor cells (OPCs) are preserved within the demyelinated lesions, suggesting that the differentiation arrest of oligodendroglial cells underlies the remyelination failure in chronic MS. We have previously reported that TIP30, a factor inhibiting nucleocytoplasmic transport within the cell, is responsible for the differentiation arrest in MS lesions. Overexpression of TIP30 in the preserved OPCs in MS lesions results in the failure of nuclear translocation of transcription factors necessary for oligodendroglial differentiation. Therefore, anti-TIP30 therapy to regain the nuclear access within the OPCs is necessary for sufficient remyelination in chronic MS patients. Moreover, inflammatory conditions surrounding OPCs may be involved in the efficient remyelination in early MS lesions, alternative stimulatory factor may therefore be mandatory to induce OPC differentiation into oligodendrocytes within the chronic lesion. We have previously reported that targeting FcRy protein on OPCs may stimulate their differentiation and consequently remyelination in the chronic lesions. A timely collaboration of these two approaches may be required for successful remyelination and neurological recovery in chronic MS patients.

AB - Spontaneous remyelination occurs in many early multiple sclerosis (MS) patients, however its capacity decreases as the disease becomes chronic. Even in those chronic MS patients, an enough number of oligodendrocyte precursor cells (OPCs) are preserved within the demyelinated lesions, suggesting that the differentiation arrest of oligodendroglial cells underlies the remyelination failure in chronic MS. We have previously reported that TIP30, a factor inhibiting nucleocytoplasmic transport within the cell, is responsible for the differentiation arrest in MS lesions. Overexpression of TIP30 in the preserved OPCs in MS lesions results in the failure of nuclear translocation of transcription factors necessary for oligodendroglial differentiation. Therefore, anti-TIP30 therapy to regain the nuclear access within the OPCs is necessary for sufficient remyelination in chronic MS patients. Moreover, inflammatory conditions surrounding OPCs may be involved in the efficient remyelination in early MS lesions, alternative stimulatory factor may therefore be mandatory to induce OPC differentiation into oligodendrocytes within the chronic lesion. We have previously reported that targeting FcRy protein on OPCs may stimulate their differentiation and consequently remyelination in the chronic lesions. A timely collaboration of these two approaches may be required for successful remyelination and neurological recovery in chronic MS patients.

KW - FcRγ

KW - Multiple sclerosis

KW - Oligodendrocytopathy

KW - Remyelination

KW - TIP30

UR - http://www.scopus.com/inward/record.url?scp=84880562526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880562526&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.52.1351

DO - 10.5692/clinicalneurol.52.1351

M3 - Article

VL - 52

SP - 1351

EP - 1353

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -